ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Acorda Therapeutics, Inc.

420 Saw Mill River Road
Ardsley, NY 10502
United States
914-347-4300
http://www.acorda.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees474

Key Executives

NameTitlePayExercisedYear Born
Dr. Ron CohenFounder, CEO, Pres & Director2.41M383.75k1956
Mr. David LawrenceChief Technology officer, Chief of Bus. Operations & Principal Accounting Officer972.6k430.83k1958
Ms. Jane WasmanPres of International, Gen. Counsel & Corp. Sec.748.86k286.77k1956
Dr. Burkhard BlankChief Medical Officer and Head of R&D1.34M230.28k1955
Ms. Felicia VonellaExec. Director of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Corporate Governance

Acorda Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.